Precision NanoSystems operates in the biotechnology sector, specializing in the development and manufacturing of RNA-based vaccines and nanomedicines. The company serves pharmaceutical and biotech companies, academic institutions, and government agencies. Precision NanoSystems leverages its proprietary NxGen technology, which uses precisely controlled mixing to generate optimal nanoparticles, facilitating the production of RNA vaccines and therapeutics at various scales. The business model includes providing end-to-end solutions for nanomedicine clinical development, such as formulation development, optimization, scale-up, and tech transfer for GMP (Good Manufacturing Practice) manufacturing. Revenue is generated through the sale of its NanoAssemblr platform, proprietary lipid formulations, and contract manufacturing services. The company also collaborates with other biotech firms to co-develop vaccines and therapeutics, further expanding its market reach.

Keywords: RNA vaccines, nanomedicine, GMP manufacturing, NxGen technology, lipid formulations, NanoAssemblr, biotech, pharmaceutical, contract manufacturing, clinical development.